Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling and marketing

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Progenity

Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enumera Molecular Formed to Develop and Commercialize Next-Generation Solutions for Liquid Biopsy Enumera Molecular Formed to Develop and Commercialize Next-Generation Solutions for Liquid Biopsy

Progenity Announces Successful Transfer of Liquid Biopsy Technologies

SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG) today announced that it will report first quarter ended March 31, 2022 financial results on Tuesday, May 10, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern time / 1:30 p.m. Pacific time that day to discuss the financial results and provide a corporate update.

Progenity to Report First Quarter Financial Results and Provide Corporate Update as Biora Therapeutics, Inc.

Expanding Leadership Team to Accelerate Development of Innovative Therapeutic Delivery Platforms Expanding Leadership Team to Accelerate Development of Innovative Therapeutic Delivery Platforms

Progenity Appoints Paul Shabram to Lead Technical Operations of the Company's Ingestible Drug/Device Platforms

Upcoming Change Reflects the Company's Focus on Oral Delivery of Biotherapeutics Upcoming Change Reflects the Company's Focus on Oral Delivery of Biotherapeutics

Progenity to Become Biora Therapeutics as it Completes Transformation

SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the acceptance of two abstracts presenting preclinical data on its systemic therapeutics delivery system for presentation at the Controlled Release Society (CRS) 2022 Annual Meeting. CRS is an international gathering of experts in the design, development, and implementation of novel drug delivery technologies. This year's meeting is focused on advanced delivery science and will take place in Montreal, Canada, July 11-15, 2022.

Progenity Announces Two Poster Presentations at Controlled Release Society 2022

Progenity, Inc. (PROG) CEO Adi Mohanty on Q4 2021 Results - Earnings Call Transcript

Accelerated Company Transformation Toward Oral Delivery of Biotherapeutics and Targeted Therapeutics Programs

Progenity Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Cenntro Inc

Didi Global

Will these penny stocks be on your watchlist in April? The post Should You Invest in These Penny Stocks Next Month?

Should You Invest in These Penny Stocks Next Month? 3 to Watch

Evelo Biosciences Inc

SeaChange International

Exela Technologies

Short squeeze stocks to watch this week. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 4 Short Squeeze Stocks To Watch This Week

SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2021 on Monday, March 28, 2022 after the close of financial markets. Progenity's management will host a webcast and conference call at 4:30 p.m. Eastern / 1:30 p.m. Pacific that day to discuss the financial results and provide a corporate update.

Progenity to Report Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update

Clinical Device Performance Study in Healthy Volunteers Demonstrated Accurate Localization and Delivery

Progenity Progresses its Drug Delivery System Clinical Device Performance Studies

SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the acceptance of three abstracts on the treatment of IBD and microbiome sampling for presentation at Digestive Disease Week® (DDW). DDW is the world's premier meeting for physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery, and will take place in person and virtually May 21-24, 2022.

Progenity Announces Acceptance of Three Abstracts at Digestive Disease Week 2022

Patient data establishes key correlations for therapeutic exposure in tissue and alternative inflammatory pathways, supporting the hypotheses of targeted therapeutic delivery and potential combination therapy for ulcerative colitis Patient data establishes key correlations for therapeutic exposure in tissue and alternative inflammatory pathways, supporting the hypotheses of targeted therapeutic delivery and potential combination therapy for ulcerative colitis

Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO'22

Dr. Bram Verstockt presented key patient data establishing correlation between drug levels in colon and clinical outcomes Dr. Bram Verstockt presented key patient data establishing correlation between drug levels in colon and clinical outcomes

Progenity Shares Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology

TC Biopharm Holdings PLC

Here's three penny stocks that investors are watching rig The post Top Penny Stocks to Buy Right Now? 3 to Watch in Mid-February   appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Buy Right Now? 3 to Watch in Mid-February

Ebang International Holdings

Phunware Inc

Reddit penny stocks are heating up, here's three to know about The post Top Reddit Penny Stocks That Investors Are Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Reddit Penny Stocks That Investors Are Watching Right Now

Vinco Ventures

Kaival Brands Innovations Group

These penny stocks climbed today, here's what you need to know The post 3 Penny Stocks Climbing During Today's Trading Session  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks Climbing During Today's Trading Session

Society Pass

Velodyne Lidar

These penny stocks climbed today, here's what you need to know The post These 4 Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

These 4 Penny Stocks Exploded Today, Here's Why

Meten Holding Group Ltd.

Check these trending penny stocks out for your watchlist The post Here's 3 Trending Penny Stocks to Add to Your Watchlist in February appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Here's 3 Trending Penny Stocks to Add to Your Watchlist in February

SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the award of another new patent related to its single-molecule detection assay platform under development. The USPTO has issued U.S. Patent No. 11,230,731 entitled, “Methods, Systems, and Compositions for Counting Nucleic Acid Molecules.” The issued claims are directed to detecting a labeled target molecule on a solid support.

Progenity Strengthens Intellectual Property for Single-Molecule Detection Technology with Additional Patent

Kosmos Energy

Reliance Global Group

Transocean

SmileDirectClub

5 Reddit penny stocks to watch right now. The post 5 Top Penny Stocks To Buy Now According To Reddit appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Penny Stocks To Buy Now According To Reddit

Aridis Pharmaceuticals

Baudax Bio

WiMi Hologram Cloud

Are these penny stocks on your watchlist for next week? The post Can These Penny Stocks Climb This Week?

Can These Penny Stocks Climb This Week? 4 To Watch Right Now

Cerberus Cyber Sentinel Corp

Paysafe

Wish

Penny stocks to watch as retail traders take aim at 2022. The post 5 Hot Meme Stocks To Buy For Pennies Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Hot Meme Stocks To Buy For Pennies Right Now

Progenity, Inc. ( PROG , Financial) is a biotech stock with an innovative pipeline. The company has been deriving its revenues from molecular laboratory tests, mainly from the sale of its Innatal, Preparent and pathology molecular testing.

Progenity: Not for the Faint-Hearted

Dr. Bram Verstockt to present patient data establishing correlation between drug levels in colon and clinical outcomes Dr. Bram Verstockt to present patient data establishing correlation between drug levels in colon and clinical outcomes

News for Progenity Stock (PROG)